Behavioral effects of non-viral mediated RNA interference of synapsin II in the medial prefrontal cortex of the rat

Schizophrenia Research

Volumn 137, Issue 1-3, 2012, Pages 32-38

  Dyck, Bailey A ^a   Tan, Mattea L ^a   Daya, Ritesh P ^a   Basu, Dipannita ^a   Sookram, Christal D R ^a   Thomas, Nancy ^a   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Behavioral testing; Medial prefrontal cortex; Schizophrenia; SiRNA; Synapsin II

Indexed keywords

SMALL INTERFERING RNA; SYNAPSIN II;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN LEVEL; CONTROLLED STUDY; GENE SILENCING; HYPERACTIVITY; LOCOMOTION; MALE; MEDIAL PREFRONTAL CORTEX; NERVE CELL NETWORK; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHENOTYPE; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; SCHIZOPHRENIA; SENSORY GATING; SOCIAL INTERACTION;

ACOUSTIC STIMULATION; ANIMALS; HYDRAZINES; MALE; MOTOR ACTIVITY; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, SMALL INTERFERING; SENSORY GATING; SOCIAL ISOLATION; STARTLE REACTION; SYNAPSINS;

EID: 84860834078     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.01.029     Document Type: Article

References (51)

1. Akaneya Y., Jiang B., Tsumoto T. RNAi-induced gene silencing by local electroporation in targeting brain region. J. Neurophysiol. 2005, 93:594-602.
2. Behlke M.A. Progress towards in vivo use of siRNAs. Mol. Ther. 2006, 13:644-670.
3. Calabresi P., Centonze D., Gubellini P., Marfia G.A., Pisani A., Sancesario G., Bernardi G. Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog. Neurobiol. 2000, 61:231-265.
4. Cesca F., Baldelli P., Valtorta F., Benfenati F. The synapsins: key actors of synapse function and plasticity. Prog. Neurobiol. 2010, 91:313-348.
5. Cheetham J.J., Murray J., Ruhkalova M., Cuccia L., McAloney R., Ingold K.U., Johnston L.J. Interaction of synapsin I with membranes. Biochem. Biophys. Res. Commun. 2003, 309:823-829.
6. Chong V., Tsang E., Gabriele J., Thomas N., Castellano J., Dyck B.A., Skoblenick K., Ki K., Mishra R.K. Decreased expression of medial prefrontal cortex synapsin II in schizophrenic specimens from the Stanley Foundation Neuropathology Consortium. Society for Neuroscience, Washington, DC, Abstract Viewer/Itinerary Planner 2005, 35:675.19. Ref Type: Abstract.
7. Chong V.Z., Skoblenick K., Morin F., Xu Y., Mishra R.K. Dopamine-D1 and -D2 receptors differentially regulate synapsin II expression in the rat brain. Neuroscience 2006, 138:587-599.
8. Chong V.Z., Skoblenick K., Morin F., Xu Y., Mishra R.K. Dopamine-D1 and -D2 receptors differentially regulate synapsin II expression in the rat brain. Neuroscience 2006, 138:587-599.
9. Chong V.Z., Young L.T., Mishra R.K. cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. J. Neurochem. 2002, 82:1533-1539.
10. Dyck B., Guest K., Sookram C., Basu D., Johnson R., Mishra R.K. PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia. Schizophr. Res. 2011, 125:88-92.
11. Dyck B.A., Beyaert M.G., Ferro M.A., Mishra R.K. Medial prefrontal cortical synapsin II knock-down induces behavioral abnormalities in the rat: examining synapsin II in the pathophysiology of schizophrenia. Schizophr. Res. 2011, 130:250-259.
12. Dyck B.A., Skoblenick K.J., Castellano J.M., Ki K., Thomas N., Mishra R.K. Synapsin II knockout mice show sensorimotor gating and behavioural abnormalities similar to those in the phencyclidine-induced preclinical animal model of schizophrenia. Schizophr. Res. 2007, 97:292-293.
13. Dyck B.A., Skoblenick K.J., Castellano J.M., Ki K., Thomas N., Mishra R.K. Behavioral abnormalities in synapsin II knockout mice implicate a causal factor in schizophrenia. Synapse 2009, 63:662-672.
14. Dykxhoorn D.M., Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu. Rev. Med. 2005, 56:401-423.
15. Engel J.A., Fahlke C., Hulthe P., Hard E., Johannessen K., Snape B., Svensson L. Biochemical and behavioral evidence for an interaction between ethanol and calcium-channel antagonists. J. Neural Transm. 1988, 74:181-193.
16. Fdez E., Hilfiker S. Vesicle pools and synapsins: new insights into old enigmas. Brain Cell Biol. 2006, 35:107-115.
17. Ferreira A., Chin L.S., Li L., Lanier L.M., Kosik K.S., Greengard P. Distinct roles of synapsin I and synapsin II during neuronal development. Mol. Med. 1998, 4:22-28.
18. Ferreira A., Rapoport M. The synapsins: beyond the regulation of neurotransmitter release. Cell. Mol. Life Sci. 2002, 59:589-595.
19. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods 1980, 2:219-238.
20. Flaherty K.T., Stevenson J.P., O'Dwyer P.J. Antisense therapeutics: lessons from early clinical trials. Curr. Opin. Oncol. 2001, 13:499-505.
21. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001, 156:117-154.
22. Gitler D., Xu Y., Kao H.T., Lin D., Lim S., Feng J., Greengard P., Augustine G.J. Molecular determinants of synapsin targeting to presynaptic terminals. J. Neurosci. 2004, 24:3711-3720.
23. Goeree R., Farahati F., Burke N., Blackhouse G., O'Reilly D., Pyne J., Tarride J.E. The economic burden of schizophrenia in Canada in 2004. Curr. Med. Res. Opin. 2005, 21:2017-2028.
24. Grillon C., Ameli R., Charney D.S., Krystal J., Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol. Psychiatry 1992, 32:939-943.
25. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122(Pt 4):593-624.
26. Hassani Z., Lemkine G.F., Erbacher P., Palmier K., Alfama G., Giovannangeli C., Behr J.P., Demeneix B.A. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. 2005, 7:198-207.
27. Kao H.T., Porton B., Czernik A.J., Feng J., Yiu G., Haring M., Benfenati F., Greengard P. A third member of the synapsin gene family. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:4667-4672.
28. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 2003, 270:1628-1644.
29. Le Pen G., Moreau J.L. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 2002, 27:1-11.
30. Lebedeva I., Stein C.A. Antisense oligonucleotides: promise and reality. Annu. Rev. Pharmacol. Toxicol. 2001, 41:403-419.
31. Locatelli F., Corti S., Papadimitriou D., Fortunato F., Del Bo R., Donadoni C., Nizzardo M., Nardini M., Salani S., Ghezzi S., Strazzer S., Bresolin N., Comi G.P. Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice. Ann. Neurol. 2007, 62:81-92.
32. Makimura H., Mizuno T.M., Mastaitis J.W., Agami R., Mobbs C.V. Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci. 2002, 3:18.
33. MatusLeibovitch N., Nevo I., Vogel Z. Differential distribution of synapsin IIa and IIb mRNAs in various brain structures and the effect of chronic morphine administration on the regional expression of these isoforms. Mol. Brain Res. 1997, 45:301-316.
34. MatusLeibovitch N., Nevo I., Vogel Z. Differential distribution of synapsin IIa and IIb mRNAs in various brain structures and the effect of chronic morphine administration on the regional expression of these isoforms. Mol. Brain Res. 1997, 45:301-316.
35. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28:53-67.
36. Rosahl T.W., Spillane D., Missler M., Herz J., Selig D.K., Wolff J.R., Hammer R.E., Malenka R.C., Sudhof T.C. Essential functions of synapsins I and II in synaptic vesicle regulation. Nature 1995, 375:488-493.
37. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 1996, 7:3-23.
38. Sams-Dodd F. Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998, 19:18-25.
39. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 1999, 10:59-90.
40. Savelli J.E., Chugh A., Cheng C., Mishra R.K., Johnson R.L. Modulation of N-methyl-d-aspartate (NMDA) antagonist-induced darting behaviour by the peptidomimetic PAMTA. Brain Res. 1995, 682:41-49.
41. Senechal Y., Kelly P.H., Cryan J.F., Natt F., Dev K.K. Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice. J. Neurochem. 2007, 102:1928-1940.
42. Sudhof T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci. 2004, 27:509-547.
43. Sudhof T.C., Czernik A.J., Kao H.T., Takei K., Johnston P.A., Horiuchi A., Kanazir S.D., Wagner M.A., Perin M.S., De Camilli P. Synapsins: mosaics of shared and individual domains in a family of synaptic vesicle phosphoproteins. Science 1989, 245:1474-1480.
44. Tcherepanov A.A., Sokolov B.P. Age-related abnormalities in expression of mRNAs encoding synapsin 1A, synapsin 1B, and synaptophysin in the temporal cortex of schizophrenics. J. Neurosci. Res. 1997, 49:639-644.
45. Tenn C.C., Fletcher P.J., Kapur S. Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr. Res. 2003, 64:103-114.
46. Tenn C.C., Kapur S., Fletcher P.J. Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology (Berl) 2005, 180:366-376.
47. Thakker D.R., Hoyer D., Cryan J.F. Interfering with the brain: use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol. Ther. 2006, 109:413-438.
48. Thakker D.R., Natt F., Husken D., Maier R., Muller M., van der P.H., Hoyer D., Cryan J.F. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:17270-17275.
49. Thakker D.R., Natt F., Husken D., van der P.H., Maier R., Hoyer D., Cryan J.F. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol. Psychiatry 2005, 10(714):782-789.
50. Walaas S.I., Browning M.D., Greengard P. Synapsin Ia, synapsin Ib, protein IIIa, and protein IIIb, four related synaptic vesicle-associated phosphoproteins, share regional and cellular localization in rat brain. J. Neurochem. 1988, 51:1214-1220.
51. Wise R.A. Brain reward circuitry: insights from unsensed incentives. Neuron 2002, 36:229-240.